ESTRO37_ProgrammeBook

16:40 > Investment cases at the global level: how can we translate successful precedents to radiotherapy? Speaker: D. Rodin (Canada)

SP-0574

MONDAY 23 APRIL 2018

17:05 > Access to radiotherapy: advocacy and policy Speaker: M. Gospodarowicz (Canada)

SP-0575

SYMPOSIUM Normal tissue dose-response modelling across radiation modalities 16:15 - 17:30  |  ROOM 111 Chair: L.P. Muren (Denmark) Co-Chair: G. Defraene (Belgium) 16:15 > Comparison and limitations of DVH-based NTCP models derived from 3D-CRT and IMRT data Speaker: M. Söhn, M. Alber (Germany) 16:33 > Clinical evidence of spatially variable proton biological effectiveness in pediatric brain tumour patients Speaker: D. Grosshans (USA), C. Peeler, D. Mirkovic, R. Mohan 16:51 > Patient-reported outcomes and associated dose response models for prostate cancer patients treated with photon vs. proton therapy Speaker: L.P. Muren (Denmark) 17:09 > Validation of photon-derived normal tissue complication probability models in a head and neck proton therapy cohort Speaker: P. Blanchard (France)

SP-0576

SP-0577

 SP-0578

SP-0579

PROFFERED PAPER RB 6: Role and impact of Normal tissue RT response biology 16:15 - 17:30  |  ROOM 120-121

Chair: G. Barnett (United Kingdom) Chair: C.N. Andreassen (Denmark)

16:15 > Radiation dose-response of locally-advanced NSCLC: Is further dose-escalation useful? M.G. Nix (United Kingdom), J.D. Fenwick

OC-0580

SCIENTIFIC PROGRAMME | Programme and Exhibition Guide

164